Date:
Location:
Rogue Therapeutics
Now that we have had our first scientific successes in precision medicine and even a new federal precision medicine initiative, will it help us treat disease? Even if we can more precisely diagnose patients and prognosticate about their future, does this mean we will have the right treatments for them? Do we have to wait for the traditional flow of science through the large pharmaceutical companies to get new effective drugs? Will engineering, whether in genetic editing or device hacking, revolutionize care?
In this symposium, we will directly address these questions and give a premeditatedly iconoclastic perspective. Our keynote speaker, Karen Aiach, did not start in medicine or pharmaceuticals, but specifically because of her long clinical journey with her daughter has founded a rapidly-growing biotech company for the treatment of the disorders of her child and those of others. We will also have panels featuring similarly patient-focused and even impatient approaches to finding therapies. As you can see from the agenda, this symposium follows very much in the spirit of our successful conference last year, Precision Medicine: Patient Driven.
Registration
Register via Eventbrite (Students and postdocs: email precisionmedicine@hms.harvard.edu for discount)
Lodging
| The Inn at Longwood Medical 342 Longwood Avenue, Boston, MA 02115 617-731-4700 Click HERE to reserve at the group rate. Cut-off date for group rate: May 31, 2016 | Courtyard Marriott Brookline 40 Webster Street (Coolidge Corner), Brookline, MA 02446 617-734-1393 Click HERE to reserve at the group rate. Cut-off date for group rate: June 20, 2016 |
Agenda
Welcome and Opening Remarks – Zak Kohane
KEYNOTE: Rare Informs the Common – Karen Aiach, Lysogene
PANEL 1: What is driving Precision Medicine?
- Ashish Jha, Harvard School of Public Health (moderator)
- Carey Goldberg, WBUR
- Joseph Newhouse, Harvard Medical School
- Gail Marcus, ELI Healthcare Consultant
PANEL 2: What happens when patients take over?
- Bill Gahl, Undiagnosed Diseases Network (moderator)
- Matt Might, University of Utah
- Eric Minikel & Sonia Vallabh, Broad Institute
- Alison Skrinar, UltraGenyx Pharmaceutical
PANEL 3: Marijuana: recreational to medicinal?
- Donald Abrams, University of California San Francisco
- Kari Franson, University of Colorado School of Pharmacy
- Ryan Vandrey, Johns Hopkins University
- Larry Wolk, Colorado Department of Public Health and Environment
PANEL 4: Will engineering disrupt therapeutics?
- Daniel Anderson, MIT
- George Church, Harvard Medical School
- Ed Damiano, Boston University
- Alison Marsden, Stanford University
CLOSING KEYNOTE: e-Patients: Empowered, Engaged, Equipped, Enabled – Dave deBronkart, ePatient Dave
Conference co-sponsored by PIC-SURE and the Department of Biomedical Informatics (DBMI)